Sorafenib, which was the only approved AAT for HCC at the time, excessively pruned vessels, thereby, causing hypoxia and stimulating the SDF1α/CXCR4 pathway (Chen et al., 2015). Here, CXCR4 is linked to hepatocellular carcinoma.